Rakovina Therapeutics Inc. (TSXV:RKV)

Canada flag Canada · Delayed Price · Currency is CAD
0.1600
+0.0150 (10.34%)
At close: Feb 9, 2026
Market Cap3.38M -87.3%
Revenue (ttm)n/a
Net Income-8.28M
EPS-0.55
Shares Out21.15M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume23,333
Average Volume37,302
Open0.1600
Previous Close0.1450
Day's Range0.1500 - 0.1600
52-Week Range0.0850 - 2.1500
Beta-0.52
RSI57.20
Earnings DateApr 28, 2026

About Rakovina Therapeutics

Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. The company’s preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series for the treatment of PARP resistant adult and childhood cancers; and kt-4000, a DNA-damaging DDR inhibitors. It has a research collaboration with Varia... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Kim Oishi
Country Canada
Stock Exchange TSX Venture Exchange
Ticker Symbol RKV
Full Company Profile

Financial Performance

Financial Statements